Synlogic's SYNB1020 well tolerated in Phase I

Synlogic Inc. (NASDAQ:SYBX) reported data from a Phase I trial in 52 healthy volunteers showing that single and multiple ascending doses of oral

Read the full 238 word article

User Sign In